Loading…
Biotech selling Livmarli and other drugs for rare pediatric liver diseases like Alagille syndrome.
Biotech selling Livmarli and other drugs for rare pediatric liver diseases like Alagille syndrome.
Sells drugs priced for very small patient groups, shipped mainly through specialty pharmacies, so growth comes from finding and treating more patients and from approvals in new countries and indications. Livmarli, approved from 2021, is the main product, with older bile-acid medicines it bought from another company adding smaller sales.
Moat: narrow (IP / patents, regulatory licence). Orphan-drug exclusivity and deep expertise in a handful of very rare pediatric liver diseases.
Headquarters: Foster City, California, United States · Founded: 2018 · Employees: 372
Size Mirum Pharmaceuticals (MIRM) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $6.12B, the 1050th largest of 3,117 United States companies the cockpit tracks. Shares closed at $93.72 on 6 Nov 2026.
Performance Over six months the shares fell 12.5%, against -1.3% for the median peer and -1.1% for the United States market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue grew 42.2% over the last twelve months (peer median +6.0%); the operating margin is -20.9% (peer median 19.6%).
Valuation It trades at 9.7× enterprise value to sales against a peer median of 4.3× (3rd most expensive of 18).
Capital Return on invested capital runs 43.4 points below its cost of capital (8.3% WACC).
Credit Mirum Pharmaceuticals has 1 bond outstanding ($690M).
Short interest Short interest is 10.3% of the free float (15 Oct 2026).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $671M | $521M | $337M | $186M | $77.1M |
| Revenue growth | — | +55% | +81% | +142% | — |
| Gross profit | $548M | $421M | $255M | $139M | $64.3M |
| EBITDA | -$113M | $2.11M | -$64.0M | -$98.3M | -$128M |
| Net income | -$904M | -$23.4M | -$87.9M | -$163M | -$136M |
| Free cash flow | -$274M | $54.9M | $9.33M | -$71.1M | -$120M |
| Capital expenditure | $37.6M | $954,000 | $21.0M | $20.1M | $278,000 |
| Total debt | $744M | $319M | $318M | $308M | $143M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals MIRM | $6.12B | -13% | +42% | -21% | 9.7× | n/a |
| Ipsen IPN.PA | $14.7B | -4% | +14% | 30% | 3.0× | -7.3% |
| Gilead Sciences GILD | $207B | +28% | +7% | 38% | 7.2× | -2.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MIRM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.2% | +1.3% | 2nd highest of 21 |
| 6-month return | -12.5% | -1.3% | 5th lowest of 20 |
| Distance from 52-week high | -27.9% | -14.8% | 8th lowest of 21 |
| Revenue growth (TTM) | +42.2% | +6.0% | 2nd highest of 17 |
| Operating margin | -20.9% | 19.6% | 3rd lowest of 18 |
| EV / Sales | 9.7× | 4.3× | 3rd most expensive of 18 |
| ROIC minus cost of capital | -43.4 pp | +1.3 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals MIRM | United States | $6.12B | -13% | +42% | -21% | 9.7× | n/a | n/a |
| Ligand Pharmaceuticals LGND | United States | $6.12B | +38% | +1% | 14% | 26.9× | 57.8% | +7.5% |
| Belite Bio, Inc. ADR BLTE | United States | $6.20B | 0% | n/a | n/a | n/a | n/a | n/a |
| Biocon BIOCON.NS | India | $6.28B | -4% | +6% | 8% | 4.3× | n/a | n/a |
| Abbott India ABBOTINDIA.NS | India | $5.93B | -1% | +6% | 28% | 8.0× | 11.4% | +10.0% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.90B | -6% | +39% | 47% | 5.4× | 1.8% | +519.6% |
| Samsung Epis 0126Z0.KS | South Korea | $6.39B | -36% | n/a | -25% | 34.5× | n/a | n/a |
| Gan & Lee Pharmaceuticals 603087.SS | China | $6.40B | +21% | +14% | 20% | 8.8× | n/a | n/a |
| Veradermics MANE | United States | $5.80B | +31% | n/a | n/a | n/a | n/a | n/a |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.48B | 0% | +4% | 14% | 1.9× | -6.3% | +18.4% |
| Ionis Pharmaceuticals IONS | United States | $6.55B | -48% | -7% | -68% | 7.7× | n/a | n/a |
| Apotex Health APTX.TO | Canada | $5.62B | n/a | +4% | 32% | 3.0× | -13.5% | +4.2% |
| Alkem Laboratories ALKEM.NS | India | $6.67B | -5% | +13% | 17% | 4.2× | 24.3% | +10.7% |
| Gland Pharma GLAND.NS | India | $5.53B | +69% | +18% | 20% | 7.8× | 28.0% | +13.3% |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |
| PTC Therapeutics PTCT | United States | $5.47B | -11% | -35% | 22% | 3.4× | 8.0% | +35.4% |
| Supernus Pharmaceuticals SUPN | United States | $5.43B | -49% | +16% | 45% | 4.1× | 4.2% | +13.9% |
| RemeGen 688331.SS | China | $6.90B | -26% | +272% | 61% | 4.9× | 2.8% | +303.3% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 2.0× | -8.2% | +10.8% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 3.2× | 15.2% | +8.7% |
| Beijing TongRenTang 600085.SS | China | $5.27B | -8% | -17% | 8% | 2.4× | 2.7% | +6.2% |
Mirum Pharmaceuticals has 1 bond outstanding with $690M face value.